

MyAir Inc. closes its Series A funding with HTH

HTH and MyAir strategic partners for the launch of Airgo, first CE marked wireless medical device for respiratory monitoring, used for Covid-19 patients in USA and Italy

Milano, 10 November 2020 - MyAir, Inc., a Boston and Milan based digital health company specialized in respiratory diagnostics, has closed its **Series A funding round** of 1 million Euro with HTH – Health Technology Holding, the proceeds of which will finance the commercial scale up and further development of the Airgo 24/7 Respiratory Monitoring Platform.

The Airgo Platform is the first 24/7 wireless Medical Grade wearable capable of real-time respiratory monitoring both in the hospital and at Home, enabling doctors to monitor continuously and remotely vital parameters and respiratory trends needed for predicting a change in a patient's health before they become critical.

Self financed to date by its founders, the MyAir Airgo platform has evolved to its 5th generation: Airgo has obtained CE Medical Device certification class II(a) and has successfully been used on over **1,000 patients for a total of 10,000 hours of monitoring** in leading hospitals in the USA (800+ patients at Harvard's Mass General Hospital, 50+ patients at Minnesota Sleep Clinic) and in Italy (250+ patients at ICS Maugeri Veruno and Ospedale S. Croce e Carle Cuneo).

Because of its **unique combination of ergonomics, autonomy, remote access 24/7, cloud based analytics and diagnostics visualization tools** through the **Airgo console**, doctors in both the USA and Italy immediately recognized the usefulness of the **Airgo device for Covid-19 patient monitoring** - where it is providing time critical information useful for promptly determining therapeutic paths.

"We are thrilled to bring in HTH and as our strategic partner; their deep experience and network, coupled with our unparalleled innovation in emerging sectors, opens up new frontiers for the future of the breathing industry", says David Kuller, founder of MyAir.

HTH, a Private Investment Company which complements the scouting activities of Zcube-Zambon Research Venture, investing directly in early stage Life Science ventures internationally, immediately recognized the value of the platform and opportunities for use in telemedicine, chronic obstructive pulmonary disease, personalized medicine, patient treatment through AI and remote physiotherapy, all amplified by the Covid-19 emergency.

According to Michele Gaiotto, HTH's CEO, "MyAir marks another important milestone in new technologies to help patients. Long before the Covid-19 pandemic we felt the need for an easy to use and reliable, continuous, and predictive monitoring tool for respiratory conditions like COPD, Asthma, etc. MyAir's technology opens up a new paradigm for managing chronic respiratory diseases."

To further enhance their strategic partnership and to explore more opportunities, HTH and MyAir are planning to open offices in OpenZone, a science campus dedicated to Health in the Milan area.

Myair Inc. was founded in 2015 to continue the development of Airgo, a technology platform invented by David Kuller for the 2013 HHS/EPA MyAir MyHealth competition - this challenge sought innovative solutions for respiratory monitoring. Airgo won the contest and \$150k, and has since been self financed by its founders. During this period Myair has evolved Airgo through 5 generations of platform technology, each validated clinically in several of the finest hospitals in America and Italy. Myair now has offices in Boston and Milan and a vast network of KOLs actively formulating Airgo based solutions to a wide variety of cardio/pulmonary/sleep diagnostics and cure. The Myair mission, together with investors, is to revolutionize healthcare using remotely gathered natural respiratory biomarkers 24/7.

<https://www.myairgo.com/>

HTH is a Private Investment Company that invests directly in Early Stage Life Science ventures, complementing the scouting activities of [Zcube-Zambon Research Venture](#) . Founded in Milan in 2019, the company invests internationally in breakthrough technologies in Biotech, Medtech and Digital Health. The company has invested in AI based drug discovery, long term drug delivery devices, innovative manufacturing technologies for novel therapies among others.

<http://www.hthvc.com/>

OpenZone is a science campus dedicated to health in the Milan area. Its mission is to create value in the health sector by promoting a dynamic community with access to competences and capital. The campus presently hosts 28 internationally recognized organizations operating in biotech, pharmaceutical and genic therapies.

OpenZone is based on open innovation, with the objective to create a bridge between different worlds, languages and competences.

www.openzone.it